Xencor Inc (NASDAQ:XNCR) Sellers Strengthened Their Shorts By 4.31%

June 29, 2018 - By Matthew Medley

Big Money Sentiment increased to 1.7 in 2018 Q1. It has change of 0.49, from 2017Q4’s 1.21. The ratio is positive due to Xencor, Inc. positioning: 7 sold and 30 reduced. 28 funds acquired holdings and 35 increased holdings. Investors holded 36.52 million in 2017Q4 but now own 43.81 million shares or 19.94% more.
Iguana Mgmt reported 35,000 shs. 23,862 were reported by D E Shaw & Com. Morgan Stanley has 87,410 shs. Jbf Incorporated holds 0.08% of its capital in Xencor, Inc. (NASDAQ:XNCR) for 16,900 shs. Bvf Il owns 902,000 shs. 872,072 are owned by Baker Bros Advsrs Lp. Prudential Inc owns 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 79,866 shs. Td Asset owns 115,044 shs. Oberweis Asset Mngmt owns 8,100 shs. Bnp Paribas Arbitrage has 8,071 shs for 0% of their capital. Royal Retail Bank Of Canada owns 1,230 shs. Alliancebernstein L P owns 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 49,200 shs. Moreover, Teacher Retirement Sys Of Texas has 0% invested in Xencor, Inc. (NASDAQ:XNCR). Millennium Llc accumulated 43,936 shs. Farallon Capital Mgmt Lc reported 0.03% of its capital in Xencor, Inc. (NASDAQ:XNCR).

Xencor, Inc. registered $16.06 million net activity with 0 buys and 9 sales since February 16, 2018. On Monday, June 18 STAFFORD JOHN S III had sold 250,000 shs worth $9.97M. Kuch John J sold $1.04M worth of Xencor, Inc. (NASDAQ:XNCR) on Wednesday, June 13. 50,000 shs were sold by Dahiyat Bassil I, worth $2.03M. Foster Paul A sold $125,050 worth of Xencor, Inc. (NASDAQ:XNCR) or 5,000 shs on Friday, February 16.

Xencor Inc (NASDAQ:XNCR) noted an increase of 4.31% in shares shorted. It was issued in June by FINRA the 2.55 million shares shorted on XNCR. Previously was reported up change of 4.31% from 2.44M shares. With Average volume 227,900, XNCR’s previous position will take 11 days to restore. 6.56% is Xencor Inc float short.

XNCR is reaching $37.56 during the last trading session, after increased 1.46%.Xencor, Inc. has volume of 71,948 shares. Since June 29, 2017 XNCR has risen 82.34% and is uptrending. XNCR outperformed the S&P 500 by 69.77%.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs.The firm is valued at $2.09 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.Last it reported negative earnings. The company??s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Total analysts of 7 have positions in Xencor Inc (NASDAQ:XNCR) as follows: 6 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 86%. Since February 22, 2018 according to StockzIntelligence Inc Xencor Inc has 13 analyst reports. On Thursday, March 15 Piper Jaffray maintained Xencor, Inc. (NASDAQ:XNCR) rating. Piper Jaffray has “Buy” rating and $40.0 target. On Monday, March 19 Wedbush maintained the shares of XNCR in report with “Outperform” rating. In Wednesday, March 28 report Leerink Swann initiated the stock with “Buy” rating. On Wednesday, February 28 Piper Jaffray maintained the shares of XNCR in report with “Buy” rating. On Thursday, April 26 the rating was maintained by Piper Jaffray with “Buy”. On Wednesday, February 28 the stock of Xencor, Inc. (NASDAQ:XNCR) earned “Buy” rating by Cantor Fitzgerald. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, March 29. On Monday, March 26 Piper Jaffray maintained Xencor, Inc. (NASDAQ:XNCR) with “Buy” rating. On Wednesday, May 9 the company was maintained by Canaccord Genuity. The company rating was maintained by Cantor Fitzgerald on Tuesday, May 8.

For more Xencor, Inc. (NASDAQ:XNCR) news brought out recently go to: Benzinga.com, Streetinsider.com, Fool.com, Gurufocus.com or Seekingalpha.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For June 7, 2018” brought out on June 07, 2018, “BTIG Starts Xencor, Inc. (XNCR) at Buy” on June 06, 2018, “3 Top Biotech Stocks to Buy Right Now” with a publish date: June 18, 2018, “Xencor to Present at Upcoming Investor Conferences” and the last “Premarket analyst action – healthcare” with publication date: June 07, 2018.

Xencor, Inc. (NASDAQ:XNCR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.